Cover Image
市場調查報告書

類風濕性關節炎治療藥的全球市場:2016∼2020年

Global Rheumatoid Arthritis Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 353175
出版日期 內容資訊 英文 126 Pages
訂單完成後即時交付
價格
Back to Top
類風濕性關節炎治療藥的全球市場:2016∼2020年 Global Rheumatoid Arthritis Drugs Market 2016-2020
出版日期: 2016年02月17日 內容資訊: 英文 126 Pages
簡介

類風濕性關節炎是在30∼60歲可見的慢性發炎性自體免疫疾病。遺傳和環境因素被認為是發病的因素。DMARD、NSAID、皮質類固醇、鎮靜劑等開發、投入為類風濕性關節炎患者的治療。全球類風濕性關節炎治療藥市場,預計2016∼2020年以年複合成長率3.43%擴大。

本報告提供全球類風濕性關節炎治療藥市場現狀與今後的成長預測,各地區趨勢,以及市場趨勢與課題,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

  • 市場焦點

第5章 疾病概要

  • 類風濕性關節炎的理解
  • 病因與病理學
  • 症狀
  • 診斷
  • 疾病的管理
  • 經濟負擔
  • 流行病學

第6章 類風濕性關節炎的生技藥品的影響

第7章 產品研發線

  • 開發平台候補作為標的的新機制
  • 臨床實驗

第8章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各類藥物市場區隔

  • DMARD
  • NSAID
  • 皮質類固醇
  • 鎮靜劑
  • 其他
  • 全球DMARD市場
  • 全球NSAID市場
  • 全球皮質類固醇市場
  • 全球鎮靜劑市場

第10章 各作用機制市場區隔

  • TNF抑制劑
  • IL-1抑制劑
  • JAK抑制劑
  • 選擇的副刺激調整劑

第11章 各分子類型市場區隔

  • 生技藥品
  • 小分子

第12章 各給藥途徑市場區隔

  • 口服
  • 非口服
  • 局部

第13章 各劑型市場區隔

  • 固體
  • 液體
  • 半固體

第14章 各地區市場區隔

  • 南北美洲
  • 美國
  • 歐洲、中東、非洲
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 法國
  • 亞太地區
  • 日本
  • 澳洲
  • 印度
  • 中國

第15章 主要國家

第16章 推動市場的要素

第17章 促進要素的影響

第18章 市場課題

第19章 促進要素及課題的影響

第20章 市場趨勢

第21章 供應商環境

  • 競爭模式
  • 市場佔有率分析
  • AbbVie
  • Amgen
  • BMS
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Pfizer
  • 其他值得注意的供應商

第22章 附錄

第23章 關於Technavio

圖表

目錄
Product Code: IRTNTR8751

About Rheumatoid Arthritis Drugs

RA is a chronic inflammatory autoimmune disease seen in people aged between 30 and 60 years. The symptoms of the disease appear slowly, with mild pain around the joints coupled with stiffness and fatigue. In the later stages, it causes inflammation of the joints. Genetic and environmental elements are known to contribute to the development of the condition. DMARDs, NSAIDs, corticosteroids, and analgesics are being developed and administered to treat individuals with RA.

Technavio's analysts forecast the global RA drugs market to grow at a CAGR of 3.43% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global RA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat the disease.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Rheumatoid Arthritis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Amgen
  • Bristol-Myers Squibb (BMS)
  • Johnson & Johnson
  • Pfizer
  • F. Hoffmann-La Roche

Other Prominent Vendors

  • Ablynx
  • Alder BioPharmaceuticals
  • Antares Medical Services
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Can-Fite BioPharma
  • Celgene
  • Celltrion
  • ChemoCentryx
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Incyte
  • KaloBios Pharmaceuticals
  • Lexicon Pharmaceuticals
  • Merck
  • Morphotek
  • Novo Nordisk
  • Regeneron Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus
  • Takeda Pharmaceuticals
  • UCB
  • Vertex Pharmaceuticals

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • Increasing costs of biologicals
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding RA
  • Etiology and pathophysiology
  • Signs and symptoms
  • Diagnosis
  • Disease management
  • Economic burden of RA
  • Epidemiology

PART 06: Impact of biologics in RA

PART 07: Pipeline portfolio

  • Novel mechanisms targeted by pipeline candidates
  • Clinical trials for RA

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by drug class

  • DMARDs
  • NSAIDs
  • Corticosteroids
  • Analgesics
  • Others
  • Global DMARDs market
  • Global NSAIDs market
  • Global corticosteroids market
  • Global analgesics market

PART 10: Market segmentation by MOA

  • TNF inhibitors
  • IL-1 blockers
  • JAK inhibitors
  • Selective costimulation modulators

PART 11: Market segmentation by type of molecule

  • Biologics
  • Small molecules

PART 12: Market segmentation by ROA

  • Oral
  • Parenteral
  • Topical

PART 13: Market segmentation by dosage form

  • Solid
  • Liquid
  • Semi-solid

PART 14: Geographical segmentation

  • RA drugs market in Americas
  • RA drugs market in US
  • RA drugs market in EMEA
  • RA drugs market in Germany
  • RA drugs market in UK
  • RA drugs market in Spain
  • RA drugs market in Italy
  • RA drugs market in France
  • Rheumatoid arthritis drugs market in APAC
  • RA drugs market in Japan
  • RA drugs market in Australia
  • RA drugs market in India
  • RA drugs market in China

PART 15: Key leading countries

PART 16: Market drivers

  • Growing older population
  • Market dominance of biologics
  • Promising drug pipeline
  • Changing lifestyle patterns
  • Advances in diagnosis technology

PART 17: Impact of drivers

PART 18: Market challenges

  • Increasing costs of biologicals
  • Loss of patent exclusivity of branded therapies
  • Use of complementary and alternative medicines (CAMs)
  • Adverse effects of drugs
  • Stringent regulations

PART 19: Impact of drivers and challenges

PART 20: Market trends

  • Emergence of biosimilars
  • Patient assistance programs
  • Popularity of off-label and traditional treatment options
  • Strategic alliances
  • Increase in public awareness

PART 21: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • AbbVie
  • Amgen
  • BMS
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Pfizer
  • Other prominent vendors

PART 22: Appendix4

  • List of abbreviations4

PART 23: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for RA drugs
  • Exhibit 03: Classification of RA based on disease severity
  • Exhibit 04: Classification of RA based on disease severity 2016
  • Exhibit 05: Etiology and pathophysiology of RA
  • Exhibit 06: Signs and symptoms of RA
  • Exhibit 07: Diagnostic tests for RA
  • Exhibit 08: Treatment options for RA
  • Exhibit 09: Non-pharmacological therapies used for RA
  • Exhibit 10: Pharmacotherapy therapy for RA
  • Exhibit 11: Drugs used to treat RA
  • Exhibit 12: Classification of surgical treatment for RA
  • Exhibit 13: Percentage share of treatment of RA 2016
  • Exhibit 14: Historical milestones in treatment of RA
  • Exhibit 15: Treatment algorithm for RA
  • Exhibit 16: Economic burden of RA
  • Exhibit 17: Annual treatment costs of RA within Europe and US 2015 ($)
  • Exhibit 18: Cost difference between biological DMARDs and non-biological DMARDs
  • Exhibit 19: Projected prevalence of RA in Americas 2010-2030 ($ millions)
  • Exhibit 20: New cases of RA in UK per year 2016
  • Exhibit 21: Existing cases of RA in UK
  • Exhibit 22: Impact of biologics on various sectors
  • Exhibit 23: Pipeline molecules for RA
  • Exhibit 24: Novel targets of pipeline candidates
  • Exhibit 25: Candidates under development: Baricitinib
  • Exhibit 26: Candidates under development: Decernotinib
  • Exhibit 27: Candidates under development: CCX354
  • Exhibit 28: Candidates under development: Sirukumab
  • Exhibit 29: Candidates under development: Infliximab biosimilar
  • Exhibit 30: Candidates under development: Secukinumab
  • Exhibit 31: Candidates under development: Bimekizumab
  • Exhibit 32: Clinical trials of RA drugs by phase 2016
  • Exhibit 33: Clinical trials of RA drugs by status 2016
  • Exhibit 34: Global RA drugs market 2015-2020 ($ billions)
  • Exhibit 35: Opportunities in RA drugs industry
  • Exhibit 36: Five forces analysis
  • Exhibit 37: Global RA drugs market segmentation by drug class
  • Exhibit 38: Examples of non-biologic DMARDs and biologic DMARDs for RA
  • Exhibit 39: NSAIDs used to treat RA
  • Exhibit 40: Market share of global RA drugs market by drug class 2015
  • Exhibit 41: Global DMARDs market 2015-2020 ($ billions)
  • Exhibit 42: Global NSAIDs market 2015-2020 ($ billions)
  • Exhibit 43: Global corticosteroids market 2015-2020 ($ billions)
  • Exhibit 44: Global analgesics market 2015-2020 ($ billions)
  • Exhibit 45: Market segmentation of global RA drugs market by MOA
  • Exhibit 46: Mean percentage of patients receiving TNF inhibitors 2010 and 2015
  • Exhibit 47: Global RA drugs market share by MOA 2015
  • Exhibit 48: Global RA drugs market segmentation by type of molecule
  • Exhibit 49: Global RA drugs market share by type of molecules 2015
  • Exhibit 50: Global RA drugs market segmentation by ROA
  • Exhibit 51: Global RA drugs market segmentation by ROA 2015
  • Exhibit 52: Global RA drugs market segmentation by dosage form
  • Exhibit 53: Global RA drugs market segmentation by dosage form 2015
  • Exhibit 54: Global RA drugs by geography 2015
  • Exhibit 55: Global RA drugs market by geography 2015-2020 ($ billions)
  • Exhibit 56: Global RA drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Exhibit 57: RA drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 58: RA drugs market in Americas by country 2015
  • Exhibit 59: RA drugs market in US 2015-2020 ($ billions)
  • Exhibit 60: RA drugs sales in US by drug class 2015
  • Exhibit 61: Drivers and challenges of RA drugs market in US
  • Exhibit 62: RA drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 63: RA drugs market in EMEA by country 2015
  • Exhibit 64: RA sales in EMEA by drug class 2015
  • Exhibit 65: RA drugs market in Germany 2015-2020 ($ billions)
  • Exhibit 66: RA drugs market in UK 2015-2020 ($ billions)
  • Exhibit 67: RA drugs market in Spain 2015-2020 ($ millions)
  • Exhibit 68: RA drugs market in Italy 2015-2020 ($ millions)
  • Exhibit 69: RA drugs market in France 2015-2020 ($ millions)
  • Exhibit 70: RA drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 71: RA drugs market in APAC by country 2015
  • Exhibit 72: RA drugs market in Japan 2015-2020 ($ billions)
  • Exhibit 73: RA drugs sales in Japan by drug class 2015
  • Exhibit 74: Drivers and challenges to growth of RA drugs market in Japan
  • Exhibit 75: RA drugs market in Australia 2015-2020 ($ millions)
  • Exhibit 76: RA drugs sales in Australia by drug class 2015
  • Exhibit 77: Drivers and challenges in RA drugs market in Australia
  • Exhibit 78: RA drugs market in India 2015-2020 ($ billions)
  • Exhibit 79: RA sales in India by drug class 2015
  • Exhibit 80: RA drugs market in China 2015-2020 ($ millions)
  • Exhibit 81: RA drugs sales in China by drug class 2015
  • Exhibit 82: Key leading countries
  • Exhibit 83: Population aged 60 years and over: World, developed and developing regions ($ millions)
  • Exhibit 84: FDA approval of biologicals
  • Exhibit 85: List of pipeline molecules
  • Exhibit 86: Lifestyle factors - Risk of rheumatoid arthritis
  • Exhibit 87: Impact of drivers
  • Exhibit 88: Average annual treatment cost of Humira, Enbrel, and Remicade 2014 ($)
  • Exhibit 89: Approval and patent expiries of top selling biologics
  • Exhibit 90: CAM therapies for RA
  • Exhibit 91: Usage of CAM in US
  • Exhibit 92: Side effects associated with RA
  • Exhibit 93: Impact of drivers and challenges
  • Exhibit 94: Patient assistance programs offered by companies
  • Exhibit 95: Revenue share of RA drugs by vendors 2015
  • Exhibit 96: YoY sales comparison of top drugs 2012-2014 ($ billions)
  • Exhibit 97: Competitive assessment of top RA drugs
  • Exhibit 98: Revenue share of RA drugs 2015
  • Exhibit 99: AbbVie: Product segmentation by revenue 2014
  • Exhibit 100: AbbVie: YoY revenue and growth rate of Humira 2012-2014 ($ billions)
  • Exhibit 101: AbbVie: YoY revenue and growth rate of Humira (in US) 2012-2014 ($ billions)
  • Exhibit 102: AbbVie: YoY revenue and growth rate of Humira (ROW) 2012-2014 ($ billions)
  • Exhibit 103: Sales of Humira in major markets
  • Exhibit 104: AbbVie: SWOT analysis
  • Exhibit 105: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2012-2014 ($ billions)
  • Exhibit 106: Amgen: YoY revenue and growth rate of Enbrel (in US) 2012-2014 ($ billions)
  • Exhibit 107: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2012-2014 ($ millions)
  • Exhibit 108: Amgen: SWOT analysis
  • Exhibit 109: BMS: Segmentation by revenue 20141
  • Exhibit 110: BMS: YoY revenue and growth rate of Orencia 2012-2014 ($ billions)
  • Exhibit 111: BMS: YoY revenue and growth rate of Orencia (in US) 2012-2014 ($ millions)
  • Exhibit 112: BMS: YoY revenue and growth rate of Orencia (ROW) 2012-2014 ($ millions)
  • Exhibit 113: Orencia sales for RA in major markets 2014
  • Exhibit 114: BMS: SWOT analysis
  • Exhibit 115: RA products by revenue 2014
  • Exhibit 116: F. Hoffmann-La Roche: YoY growth and revenue generated from product sales of MabThera/Rituxan 2011-2014 ($ billions)
  • Exhibit 117: MabThera/Rituxan geographic segmentation by revenue 2014
  • Exhibit 118: F.Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2012-2014 ($ millions)
  • Exhibit 119: Actemra/RoActemra geographic segmentation by revenue 2014
  • Exhibit 120: F. Hoffmann-La Roche: SWOT analysis
  • Exhibit 121: Johnson & Johnson: Segmentation of key drugs 2014
  • Exhibit 122: Johnson & Johnson: YoY growth rate and revenue of Remicade 2012-2014 ($ billions)
  • Exhibit 123: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2012-2014 ($ billions)
  • Exhibit 124: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2012-2014 ($ billions)
  • Exhibit 125: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2012-2014 ($ millions)
  • Exhibit 126: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (in US) 2012-2014 ($ millions)
  • Exhibit 127: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2012-2014 ($ millions)
  • Exhibit 128: Johnson & Johnson: SWOT analysis
  • Exhibit 129: Pfizer: Rhematoid drugs product segmentation by revenue 2014
  • Exhibit 130: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2012-2014 ($ billions)
  • Exhibit 131: Pfizer: YoY revenue and growth rate of Celebrex 2012-2014 ($ billions)
  • Exhibit 132: Pfizer: YoY revenue and growth rate of Xeljanz 2012-2014 ($ billions)
  • Exhibit 133: Pfizer: SWOT analysis
Back to Top